GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Exchange: NYSE
Symbol: GSK
CUSIP:

Key Metrics:

Previous Close: $42.90
50 Day Moving Average: $43.65
200 Day Moving Average: $42.73
52-Week Range: $37.82 - $45.58
Trailing P/E Ratio: 2681.25
Foreward P/E Ratio: 15.49
P/E Growth: 1.68
Market Cap: $104.27B
Outstanding Shares: 2,430,500,000
Beta: 0.85

Profitability:

Net Margins: 0.21%
Return on Equity: 56.57%
Return on Assets: 7.57%

Debt:

Debt-to-Equity Ratio: 3.57%
Current Ratio: 0.93%
Quick Ratio: 0.63%

Additional Links:

Companies Related to GlaxoSmithKline PLC:

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (?)

Ratings Breakdown:	2 Sell Ratings, 9 Hold Ratings, 10 Buy Ratings
Consensus Rating:	Hold (Score: 2.38)
Consensus Price Target:	$48.25 (12.47% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)

Show:

Date	Firm	Action	Rating	Price Target
9/23/2016	Citigroup Inc.	Reiterated Rating	Buy
9/23/2016	Piper Jaffray Cos.	Initiated Coverage	Overweight
9/22/2016	JPMorgan Chase & Co.	Reiterated Rating	Neutral
9/20/2016	Bank of America Corp.	Reiterated Rating	Buy	$50.00
9/16/2016	Beaufort Securities	Reiterated Rating	Buy
9/14/2016	Jefferies Group	Reiterated Rating	Buy
9/13/2016	BNP Paribas	Downgrade	Neutral -> Underperform
9/12/2016	HSBC	Reiterated Rating	Buy
8/17/2016	Shore Capital	Reiterated Rating	Hold
8/12/2016	Argus	Boost Price Target	Buy	$48.00 -> $50.00
7/28/2016	Goldman Sachs Group Inc.	Reiterated Rating	Buy
6/27/2016	Deutsche Bank AG	Reiterated Rating	Hold
5/26/2016	Cowen and Company	Downgrade	Outperform -> Market Perform
5/5/2016	Oddo Securities	Upgrade	Reduce -> Buy
2/26/2016	Cantor Fitzgerald	Initiated Coverage	Hold
2/4/2016	Sanford C. Bernstein	Boost Price Target	Market Perform	$43.00 -> $45.00
1/27/2016	Bryan, Garnier & Co	Upgrade	Neutral -> Buy
12/21/2015	Leerink Swann	Reiterated Rating	Market Perform	$48.00
11/6/2015	Morgan Stanley	Reiterated Rating	Neutral
10/31/2015	Societe Generale	Reiterated Rating	Sell
10/20/2015	Credit Suisse Group AG	Upgrade	Underperform -> Neutral
6/26/2015	Liberum Capital	Upgrade	Sell -> Hold
5/22/2015	Berenberg Bank	Reiterated Rating	Hold
4/16/2015	Barclays PLC	Reiterated Rating	Overweight
3/30/2015	Kepler Capital Markets	Reiterated Rating	Hold
2/6/2015	Panmure Gordon	Reiterated Rating	Hold
2/5/2015	S&P Equity Research	Downgrade	Hold
1/22/2015	New Street Research	Downgrade	Reduce

(Data available from 9/29/2014 forward)

Earnings History for GlaxoSmithKline PLC (NYSE:GSK)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/3/2016	Q415	$0.18	$0.18	$6.28 billion	$6.29 billion	View	N/A
10/28/2015	Q3	$0.60	$0.71	$6.07 billion	$6.13 billion	View	N/A
7/29/2015	Q215	$0.50	$0.53			View	N/A
5/6/2015	Q115	$0.55	$0.48			View	N/A
2/4/2015	Q414	$0.86	$0.82	$6.14 billion	$6.19 billion	View	N/A
10/22/2014	Q314	$0.79	$0.90			View	Listen
7/23/2014	Q114	$0.71	$0.65			View	N/A
4/30/2014	Q413	$0.72	$0.70			View	N/A
2/5/2014	Q4	$0.30	$0.30	$6.84 billion	$6.91 billion	View	N/A
10/23/2013	Q313		$0.31	$10.31 billion	$10.09 billion	View	N/A
7/24/2013		$0.26	$0.26		$6.62 billion	View	N/A
4/25/2012		$0.29	$0.27			View	N/A
2/7/2012		$0.30	$0.28			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Current Year EPS Consensus Estimate: $2.60 EPS
Next Year EPS Consensus Estimate: $2.77 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	$0.50	$0.50	$0.50
Q2 2016	2	$0.54	$0.55	$0.55
Q3 2016	1	$0.77	$0.77	$0.77
Q4 2016	1	$0.65	$0.65	$0.65

(Data provided by Zacks Investment Research)

Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)

Annual Dividend:	$1.98
Dividend Yield:	4.62%
Dividend Growth:	2.50% (3 Year Average)
Payout Ratio:	6,600.00% (Based on Trailing 12 Months of Earnings) 76.15% (Based on Current Year Consensus EPS Estimate) 71.48% (Based on Next Year Consensus EPS Estimate)

Dividend History for GlaxoSmithKline PLC (NYSE:GSK)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/27/2016		$0.49		8/10/2016	8/12/2016	10/13/2016
4/28/2016		$0.55		5/11/2016	5/13/2016	7/14/2016
10/28/2015		$0.58		11/10/2015	11/13/2015	1/14/2016
5/7/2015	quarterly	$0.58	5.22%	5/13/2015	5/15/2015	7/9/2015
2/5/2015	quarterly	$0.70	6.05%	2/18/2015	2/20/2015	4/9/2015
10/23/2014	quarterly	$0.61	5.41%	11/5/2014	11/7/2014	1/8/2015
7/24/2014	quarterly	$0.65	5.18%	8/6/2014	8/8/2014	10/2/2014
5/1/2014	quarterly	$0.64	4.62%	5/14/2014	5/16/2014	7/10/2014
2/5/2014		$0.75		2/19/2014	2/21/2014	4/10/2014
2/6/2014	quarterly	$0.75	5.73%	2/19/2014	2/21/2014	4/10/2014
10/24/2013	quarterly	$0.62	4.76%	11/13/2013	11/15/2013	1/9/2014
7/25/2013	quarterly	$0.55	4.27%	8/7/2013	8/9/2013	10/3/2013
4/25/2013	quarterly	$0.55	4.25%	5/8/2013	5/10/2013	7/11/2013
2/7/2013	quarterly	$0.07	0.61%	2/20/2013	2/22/2013	4/11/2013

(Data available from 1/1/2013 forward)

Insider Trading History for GlaxoSmithKline PLC (NYSE:GSK)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)

Date	Headline
	GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare (NYSE:GSK) www.pressreleasepoint.com - September 29 at 5:13 PM
	The Highest-Yielding Drug Stocks (NYSE:GSK) www.fool.com - September 29 at 5:13 PM
	BRIEF-GlaxoSmithKline appoints new consumer healthcare CEO (NYSE:GSK) www.reuters.com - September 29 at 10:23 AM
	GlaxoSmithKline : Glaxo Appoints McNamara To Succeed Walmsley In Consumer Healthcare (NYSE:GSK) www.4-traders.com - September 29 at 10:23 AM
	GlaxoSmithKline Appoints New Consumer Healthcare Chief (NYSE:GSK) ih.advfn.com - September 29 at 10:23 AM
	GlaxoSmithKline Plc (NYSE:GSK), Oncodesign Sign Deal For Francois Hyafil Research Center Acquisition (NYSE:GSK) marketexclusive.com - September 29 at 10:23 AM
	After CEO move, GSK picks ex-Novartis exec to head consumer unit (NYSE:GSK) uk.finance.yahoo.com - September 29 at 10:23 AM
	After CEO move, GSK picks ex-Novartis executive to head consumer unit (NYSE:GSK) sg.finance.yahoo.com - September 29 at 10:23 AM
	Glaxo Appoints Brian McNamara Chief of Consumer Health Division (NYSE:GSK) www.bloomberg.com - September 29 at 10:23 AM
	GlaxoSmithKline (GSK) Stock Down, McNamara Named CEO of Consumer Healthcare Unit (NYSE:GSK) www.thestreet.com - September 29 at 10:22 AM
	GlaxoSmithKline announces intention to sell remaining holding in Aspen (NYSE:GSK) www.publicnow.com - September 29 at 10:22 AM
	GlaxoSmithKline completes sale of remaining Aspen shares (NYSE:GSK) www.publicnow.com - September 29 at 10:22 AM
	GlaxoSmithKline to sell remaining stake in Aspen (NYSE:GSK) www.marketwatch.com - September 28 at 5:08 PM
	Is GlaxoSmithKline plc (NYSE:GSK), a large market cap stock a smart buy? (NYSE:GSK) twincountynews.com - September 28 at 5:08 PM
	Ariel Funds Comments on GlaxoSmithKline plc (NYSE:GSK) finance.yahoo.com - September 28 at 5:08 PM
	GlaxoSmithKline plc (ADR) (GSK) Steps ahead in Lupus Treatment - Smаrt Stоck Nеws (NYSE:GSK) www.smartstocknews.com - September 28 at 10:11 AM
	GlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner (NYSE:GSK) www.thestreet.com - September 28 at 10:11 AM
	Teva Is Well Placed to Dominate the European Generics Market (NYSE:GSK) marketrealist.com - September 28 at 10:11 AM
	Fighting Addiction and Other Unmet Medical Needs with Cannabidiol (NYSE:GSK) www.prnewswire.com - September 27 at 9:56 AM
	Top Gainers of the Day: GlaxoSmithKline plc (NYSE:GSK) from Drug Manufacturers – Major (NYSE:GSK) twincountynews.com - September 27 at 9:56 AM
	Vigorous Stocks Need to Consider: GlaxoSmithKline plc (NYSE:GSK), Encana Corporation (NYSE:ECA), L Brands, Inc ... - Street Wise Report (press release) (blog) (NYSE:GSK) streetwisereport.com - September 26 at 5:28 PM
	Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S. (NYSE:GSK) finance.yahoo.com - September 26 at 9:59 AM
	GSK Submits for Subcutaneous Formulation of Benlysta in US, Europe (NYSE:GSK) ih.advfn.com - September 23 at 10:18 AM
	GSK Announces U.S. Regulatory Submission For Sirukumab In Rheumatoid Arthritis (NYSE:GSK) www.nasdaq.com - September 23 at 10:18 AM
	GlaxoSmithKline : Files US Regulatory Application for Sirukumab in Rheumatoid Arthritis (NYSE:GSK) www.4-traders.com - September 23 at 10:18 AM
	[$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience (NYSE:GSK) www.ft.com - September 23 at 10:18 AM
	US Regulatory Submission for sirukumab in RA (NYSE:GSK) www.publicnow.com - September 23 at 10:18 AM
	GSK announces US regulatory submission for sirukumab in rheumatoid arthritis (NYSE:GSK) www.publicnow.com - September 23 at 10:18 AM
	AlphaValue Reaffirms “Buy” Rating for GlaxoSmithKline plc (GSK) - Petro Global News 24 (NYSE:GSK) petroglobalnews24.com - September 22 at 5:23 PM
	52-week High/Low: - Proactive Investors UK (NYSE:GSK) www.proactiveinvestors.co.uk - September 21 at 3:32 PM
	Trending Stock - GlaxoSmithKline plc's (GSK) - Hot Stocks Point (NYSE:GSK) www.hotstockspoint.com - September 21 at 3:32 PM
	Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix - Insider Monkey (blog) (NYSE:GSK) www.insidermonkey.com - September 21 at 3:32 PM
	Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix (NYSE:GSK) feedproxy.google.com - September 20 at 3:55 PM
	Medecins Sans Frontieres Happy with GlaxoSmithKline plc (ADR) (NYSE:GSK) Price Reduction For Synflorix - Market Exclusive (NYSE:GSK) marketexclusive.com - September 20 at 10:26 AM
	Glaxo Names Consumer Head Emma Walmsley to Succeed Witty as CEO - Bloomberg (NYSE:GSK) www.bloomberg.com - September 20 at 10:26 AM
	High Market Cap Stock of the Day – GlaxoSmithKline plc (NYSE:GSK) (NYSE:GSK) twincountynews.com - September 19 at 5:24 PM
	HC Stocks in Drift! GlaxoSmithKline plc (ADR) (GSK), Acadia Healthcare Company Inc (NASDAQ:ACHC) - share market updates (press release) (NYSE:GSK) sharemarketupdates.com - September 19 at 9:54 AM
	GSK cuts vaccine price for refugees, bowing to pressure (NYSE:GSK) sg.finance.yahoo.com - September 19 at 9:54 AM
	GSK appoints Raj Khemani as IT lead (NYSE:GSK) www.infotechlead.com - September 18 at 9:49 AM
	Drugmakers Must Report Clinical Trial Results Once Kept Secret (NYSE:GSK) www.investors.com - September 16 at 5:11 PM
	GSK closes UK factory due to flooding (NYSE:GSK) sg.finance.yahoo.com - September 16 at 9:10 AM
	Roche’s Oncology Wheelhouse Stacked with Competitive Drugs (NYSE:GSK) marketrealist.com - September 16 at 9:10 AM
	Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine (NYSE:GSK) finance.yahoo.com - September 15 at 5:40 PM
	Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price (NYSE:GSK) marketrealist.com - September 15 at 5:40 PM
	4 Foreign Stocks to Fire Up Your Portfolio (NYSE:GSK) www.thestreet.com - September 15 at 5:40 PM
	Bullish on SoftBank, ASML, Royal Dutch Shell and GlaxoSmithKline (NYSE:GSK) www.thestreet.com - September 15 at 5:40 PM
	MEDICAL & HEALTHCARE JOB \| Recruitment Lead at GlaxoSmithKline (GSK) (NYSE:GSK) bizwatchnigeria.ng - September 15 at 8:24 AM
	GlaxoSmithKline's shingles vaccine lasts four years in elderly patients (NYSE:GSK) www.proactiveinvestors.co.uk - September 15 at 8:24 AM
	GlaxoSmithKline : GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis \| GSK (NYSE:GSK) www.4-traders.com - September 15 at 8:24 AM
	Form 6-K GLAXOSMITHKLINE PLC For: Sep 15 (NYSE:GSK) www.streetinsider.com - September 15 at 8:24 AM